Dermata Therapeutics DRMA 深 沪
等待开盘 08-27 09:30:00 美东时间
5.50
-0.330
-5.66%
华盛通- 最 高5.84
- 今 开5.74
- 成交量 3.68万股
- 最 低 5.34
- 昨 收 5.83
- 总市值 3507.96万
- 52周最高 24.90
- 市盈率 静 --
- 换手率 0.58%
- 52周最低 5.09
- 委 比 -69.49%
- 总股本 637.81万
- 历史最高 16680.00
- 量 比 1.39
- 振 幅 8.58%
- 历史最低 5.34
- 每 手 1
- 风险率 3.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Dermata Therapeutics Regains Nasdaq Compliance by August 2025
The latest announcement is out from Dermata Therapeutics ( ($DRMA) ). On May 14...
08-26 05:32
Maxim Group Maintains Buy on Dermata Therapeutics, Lowers Price Target to $10
Maxim Group analyst Anthony Vendetti maintains Dermata Therapeutics (NASDAQ:DRMA) with a Buy and lowers the price target from $30 to $10.
08-22 00:32
Australian Patent Office Dermata Therapeutics Patent Application For DMT410 Program For Hyperhidrosis Titled "Compositions for the treatment of skin conditions," (Australian Patent No. 2109284621)
- This is the Company's second granted patent for DMT410, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis -- The Company recently entered into a Clinical Trial Collaboration
07-08 20:11
Dermata Faces Nasdaq Delisting Risk, Plans Stock Split
Dermata Therapeutics ( ($DRMA) ) has issued an announcement. On May 14, 2025, D...
07-08 05:49
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers ENDRA Life Sciences (NASDAQ:NDRA) stock increased by 50.4% to $5.2 dur...
07-08 05:06
Maxim Group Maintains Buy on Dermata Therapeutics, Lowers Price Target to $3
Maxim Group analyst Anthony Vendetti maintains Dermata Therapeutics (NASDAQ:DRMA) with a Buy and lowers the price target from $6 to $3.
05-21 22:51
Dermata Therapeutics Begins Manufacturing for STAR-2 Trial
Dermata Therapeutics ( ($DRMA) ) has provided an update. On May 20, 2025, Derma...
05-21 21:31
Dermata Reports Positive Phase 3 Trial Results
Dermata Therapeutics ( ($DRMA) ) just unveiled an update. In the first quarter ...
05-14 21:30
Nano-Cap Dermata Therapeutics Unveils Positive Data From Once Weekly Drug Study For Acne
Dermata's Xyngari showed significant acne improvement in Phase 3 results. A second pivotal trial is set for the second half of 2025.
03-27 22:21
